Viewing Study NCT07185256


Ignite Creation Date: 2025-12-24 @ 11:24 PM
Ignite Modification Date: 2025-12-25 @ 9:10 PM
Study NCT ID: NCT07185256
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2025-07-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Sponsor: Opus Genetics, Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module